痛风的药物治疗进展

目的:系统性回顾分析并总结治疗痛风的新的药物进展。方法:对近年国内外文献进行系统性回顾,归纳总结了痛风不同阶段的新的药物的进展。结果:痛风急性发作期,非甾体消炎药、秋水仙碱、激素为一线用药,白介素-1受体拮抗剂对传统药物有禁忌的患者疗效好。间歇期和慢性期治疗中,非布司他疗效和耐受性好,尿酸酶可有效降低血尿酸水平。结论:痛风的药物治疗不同时期均有新的药物,如白介素-1受体拮抗剂、非布司他、尿激酶等均有良好疗效,为临床医生治疗痛风时提供了更多的选择。

Progress in the Pharmacotherapy of Gout

Objective： To systemically study the progress of the drugs in gout treatment. Methods： To systemically review the literatures both domestic and abroad in recent years, and summarize the new progress of the drugs in different period of gout treatment. Results： NSAIDs, colchicine and corticosteroid are considered to be the first-line option for acute gout. IL-1 receptor antagonist is good for the patients with contraindications to traditional medicines. In the period of chronic gout treatment, febuxostat has good efficiency and tolerance. Uricase can also lower uric acid levels effectively. Conclusion： In recent years, there are new drugs such as IL-1 receptor antagonist, febuxostat and uricase, which are used in different period of gout. The new drugs endow the clinicians with more choices in the treatment of gout.